Form 4: PTC Therapeutics SVP Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
Summary
- On January 7, 2025, Christine Marie Utter, SVP and Chief Accounting Officer of PTC Therapeutics, sold 1,291 shares of common stock at a price of $45.34 per share.
- This sale was to cover tax withholding obligations related to the vesting of 3,500 RSUs from a January 5, 2023 grant.
- On January 8, 2025, Utter sold an additional 1,662 shares at $44.50 per share to cover tax obligations related to the vesting of RSUs from grants made on January 6, 2021, and January 7, 2022.
- Following these transactions, Utter beneficially owns 64,321 shares of PTC Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock sales for tax purposes, indicating a neutral sentiment.
Industry Context
Form 4 filings are a routine part of the stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.
Stakeholder Impact
- The stock sales could have a minor, temporary impact on the stock price, but are unlikely to significantly affect stakeholders.
Key Dates
| Date | Description |
|---|---|
| 2021-01-06 | Date of original grant of 8,700 RSUs |
| 2022-01-07 | Date of original grant of 11,600 RSUs |
| 2023-01-05 | Date of original grant of 14,000 RSUs |
| 2025-01-07 | Sale of 1,291 shares at $45.34 |
| 2025-01-08 | Sale of 1,662 shares at $44.50 |
| 2025-01-10 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.